Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma
Alaghehbandan R, Stehlik J, Trpkov K, Magi-Galluzzi C, Mundo EC, Foix MP, Berney D, Sibony M, Suster S, Agaimy A, Montiel DP, Pivovarcikova K, Michalova K, Daum O, Ondic O, Rotterova P, Dusek M, Hora M, Michal M, Hes O (2017)
Publication Type: Journal article
Publication year: 2017
Journal
Book Volume: 29
Pages Range: 17-22
DOI: 10.1016/j.anndiagpath.2017.04.007
Abstract
Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare and aggressive tumor affecting mostly younger patients. This is the first study to assess the expression of programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) in FH-RCC. Formalin-fixed paraffin-embedded samples from 13 FH-RCCs collected in an international multi-institutional study, were evaluated by immunohistochemistry (IHC) for PD-1/PD-L1 reactivity in tumor cells and tumor infiltrating lymphocytes (TILs). PD-1/PD-L1 expression was further evaluated by qPCR. By IHC, PD-1 was negative in tumor cells in all 13 cases. PD-L1 was positive in tumor cells in 2/13 cases, weak positive in 7/13, and negative in 4/13 cases, respectively. In TILs, PD-1 was positive in 1/13, weak positive in 3/13, and negative in 9/13 cases. In TILs, PD-L1 was weak positive by IHC in 5/13, and negative in 8/13 cases, respectively. qPCR confirmed the result for 2 of 3 IHC weak positive PD-1 samples. Of 7 IHC weak positive samples (in tumor cells), PD-L1 mRNA was detected in all 7 tumors. The majority of FH-RCCs did not express PD-1/PD-L1 by IHC, which was confirmed by molecular analysis. PD-1/PD-L1 expression in FH-RCC is restricted to a proportion of cases which may benefit from targeted therapies.
Authors with CRIS profile
Involved external institutions
Univerzita Karlova v Praze / Charles University in Prague
Czech Republic (CZ)
University of British Columbia
Canada (CA)
Charles University Hospital Pilsen
Czech Republic (CZ)
Instituto Nacional de Cancerología
Mexico (MX)
Medical College of Wisconsin (MCW)
United States (USA) (US)
Hôpital Cochin
France (FR)
Barts Cancer Institute
United Kingdom (GB)
Bellvitge Biomedical Research Institute (IDIBELL)
Spain (ES)
Cleveland Clinic
United States (USA) (US)
University of Calgary
Canada (CA)
Czech Republic (CZ)
University of British Columbia
Canada (CA)
Charles University Hospital Pilsen
Czech Republic (CZ)
Instituto Nacional de Cancerología
Mexico (MX)
Medical College of Wisconsin (MCW)
United States (USA) (US)
Hôpital Cochin
France (FR)
Barts Cancer Institute
United Kingdom (GB)
Bellvitge Biomedical Research Institute (IDIBELL)
Spain (ES)
Cleveland Clinic
United States (USA) (US)
University of Calgary
Canada (CA)
How to cite
APA:
Alaghehbandan, R., Stehlik, J., Trpkov, K., Magi-Galluzzi, C., Mundo, E.C., Foix, M.P.,... Hes, O. (2017). Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma. Annals of Diagnostic Pathology, 29, 17-22. https://doi.org/10.1016/j.anndiagpath.2017.04.007
MLA:
Alaghehbandan, Reza, et al. "Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma." Annals of Diagnostic Pathology 29 (2017): 17-22.
BibTeX: Download